Mounjaro Dosage Chart 2026: Approved Schedule, KwikPen Strengths, and Zepbound Differences
The approved Mounjaro and Zepbound (tirzepatide) dosage chart, reproduced for reference from the FDA-approved product label: six named strengths, the label's four-week interval structure, KwikPen formats, and the difference between the diabetes and weight-management brands. This page reproduces a published regulatory document as reference information only. It is not an instruction to any reader, and prescribing decisions belong to a licensed clinician.
The Approved Chart (per the FDA-Approved Label)
Mounjaro is the diabetes brand of tirzepatide. As a matter of label fact, the FDA-approved label names six strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — on a once-weekly schedule. The label's chart is organized in four-week intervals across those six named strengths. The label identifies 2.5 mg as the entry strength and names the approved maintenance range as 5-15 mg; the approved mounjaro max dose is named as 15 mg weekly, as it is for Zepbound. This section reproduces the structure of a published regulatory document; it does not direct any reader to take any amount, and it names no step for any individual. Search queries for a "mounjaro dosage chart" or a "tirzepatide dosage chart" map to this same published six-strength table.
KwikPen Strengths and Delivery Math
Mounjaro and Zepbound are dispensed as KwikPen single-patient pens delivering four weekly doses each, in the six strengths; the shared label numbers are why a "zepbound dosage chart" matches the Mounjaro table. Because the label's table is organized in four-week intervals, the label notes that pens are not strength-interchangeable mid-series without a prescriber's direction, and it addresses missed-dose handling for the prescribing clinician. For anyone cross-referencing reported quantities, our conversion tool performs concentration and volume math on stated amounts — lab reference arithmetic, not dosing guidance.
Dose-Response: What the Trial Numbers Reported
The tirzepatide dose-response curve reported in the SURMOUNT trial series is one of the cleanest in the class: mean weight loss climbed with strength, from about 15% at 5 mg toward 20-21% at 10-15 mg over 72 weeks, with the Zepbound label naming 15 mg as the top strength for maximal responders. The SURPASS (diabetes) trials report the same pattern for HbA1c. That dose-response is why the label's table is organized in four-week intervals: higher strengths were associated with more efficacy and more GI-side-effect burden in the reported data. Our semaglutide-vs-tirzepatide guide compares the two approved schedules side by side, including the difference between semaglutide's 2.4 mg weekly figure and tirzepatide's 15 mg weekly maximum.
Mounjaro vs Zepbound vs What Comes Next
The brand split is the most common confusion point: Mounjaro = tirzepatide for type 2 diabetes, Zepbound = tirzepatide for weight management, same molecule and same approved chart. Search variants such as "munjaro doses" and "manjaro dosing" are common misspellings of the same approved tirzepatide table reproduced above. Zepbound lawsuits over claimed side effects (gastroparesis reports) are active in 2026 — our news section tracks the litigation as it develops, and the label places the schedule and oversight with a licensed prescriber. Beyond tirzepatide, retatrutide's trial results (up to 31%) define the next investigational rung and oral orforglipron the convenience tier; our reference tables cover each approved and investigational schedule.
📊 Dosage Calculator & Protocol Chart
Convert reported label amounts into concentration and volume figures for reference:
👉 Mounjaro Dosage Calculator — Concentration and volume conversions for the amounts named in the approved label.
👉 Full Dosing Guide & Protocol Chart — The approved chart, reported trial data, and study parameters in one reference place.
Important Disclaimer
This article is for educational and research purposes only. Mounjaro and Zepbound are FDA-approved products; this page reproduces their approved label chart for reference, and nothing here is medical advice or a prescribing recommendation. Prescribing decisions belong to a licensed clinician. The information provided here is synthesized from published research, clinical trial data, and community discussions.
Keywords: mounjaro dosage chart, munjaro doses, mounjaro max dose, tirzepatide dosage chart, zepbound dosage chart, manjaro dosing
Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content